Jazz Pharmaceuticals (JAZZ) FY2025 10-K Risk Factors: 12 New, 6 Dropped

What the changes say

Jazz Pharmaceuticals faces increased scrutiny over drug pricing, government reimbursement programs, and compliance with controlled substance regulations.
The Chimerix acquisition introduces integration risks, litigation matters, and reliance on new product pipelines like Modeyso.
Expanded risk disclosures cover emerging threats from artificial intelligence adoption and supply chain cybersecurity vulnerabilities.

What changed since the prior 10-K

New

NewRisks Related to Our Lead Products and Product Candidates
Legislative and regulatory proposals to reform the regulation of the pharmaceutical industry and reimbursement for pharmaceutical drugs are continually changing, and all such considerations may adversely affect our business and industry in ways that we cannot accurately predict
Legislative and regulatory proposals targeting pharmaceutical drug pricing and healthcare reimbursement could negatively impact our product revenues and marketing approvals.
NewRisks Related to Our Lead Products and Product Candidates
could negatively impact our anticipated revenues and could potentially cause us to breach contractual obligations with customers or to violate local laws requiring us to deliver the product to those in need
Manufacturing Epidiolex/Epidyolex requires complex adherence to GMP standards, botanical raw material cultivation, and strict supply chain controls across international sites.
NewRisks Related to Growth of Our Product Portfolio and Research and Development
We may not realize the anticipated benefits from our acquisition of Chimerix
Our April 2025 acquisition of Chimerix and its product Modeyso may fail to deliver anticipated benefits or require higher resources and investments than expected.
NewRisks Related to Growth of Our Product Portfolio and Research and Development
As a result of these or other factors, products or product candidates we acquire, or obtain licenses to, may not produce the revenues, earnings or business synergies that we anticipated, may not result in regulatory approvals, and may not perform as expected
Acquired products or licensed product candidates may fail to produce expected revenues, achieve regulatory approvals, or yield anticipated business synergies.
NewRisks Related to Our Intellectual Property
methods do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid or unenforceable, which we may not be able to do
Intellectual property disputes or failure to secure valid assignment agreements could require us to pay treble damages or suspend product manufacturing.
NewRisks Related to Our Intellectual Property
attacks have increased in frequency and severity, and we cannot guarantee that third parties’ infrastructure in our supply chain or our third-party partners’ supply chains have not been compromised
Cybersecurity incidents and supply chain disruptions can compromise sensitive data, leading to regulatory enforcement actions, litigation, and reputational harm.
NewRisks Related to Our Intellectual Property
Our adoption of AI technologies introduces new risks and uncertainties
Our adoption of artificial intelligence technologies introduces risks regarding data accuracy, cybersecurity vulnerabilities, and evolving global regulatory compliance.
NewRisks Related to Our Intellectual Property
in our revenues from the affected products and harm to our reputation and could have a significant impact on our sales, business and financial condition
Adverse event reporting and safety signal reviews by the FDA and EMA could result in label changes, sales restrictions, or marketing suspensions.
NewRisks Related to Our Intellectual Property
Other Regulatory Authorities
Global sales, marketing, and patient support activities are subject to intensive scrutiny under fraud and abuse laws enforced by agencies like the DEA, DOJ, and OIG.
NewRisks Related to Our Intellectual Property
significantly impact the ability of FDA to timely review and process our regulatory submissions or take other actions critical to the marketing of our products which could have a material adverse effect on our business
Failure to comply with reporting and payment obligations under the Medicaid Drug Rebate Program, 340B, and Medicare ASP programs could result in severe penalties.
NewRisks Related to Controlled Substances
requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under federal law
U.S. facilities handling controlled substances must maintain strict DEA registrations and state compliance to avoid civil penalties, suspensions, or operational delays.
NewRisks Related to Our Financial Condition and Results
We are subject to reviews and audits by the IRS, and other taxing authorities from time to time, and the IRS or other taxing authority may challenge our structure, transfer pricing arrangements and tax positions through an audit or lawsuit
Tax authorities such as the IRS may challenge our corporate structure, transfer pricing, and tax positions, resulting in potential back taxes and penalties.

Dropped

DroppedRisks Related to Our Lead Products and Product Candidates
for us and/or take a significant amount of time, any of which could materially and adversely affect our business, financial condition, results of operations and growth prospects
DroppedRisks Related to Our Intellectual Property
Leahy-Smith America Invents Act permits any person, whether they are accused of infringing the patent at issue or not, to challenge the validity of certain patents through a proceeding before the PTAB of the USPTO
DroppedRisks Related to Our Intellectual Property
In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive data about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position
DroppedRisks Related to Our Intellectual Property
of these products exceeding historical sales on a named patient basis could have an adverse effect on our business, financial condition, results of operations and growth prospects
Hikma generic high-sodium oxybate REMS waiver and separate program pharmacy verification requirements.
DroppedRisks Related to Our Intellectual Property
We are also subject to regulation by other regional, national, state and local agencies, including the DEA, the DOJ, the FTC, the United States Department of Commerce, the OIG, and other regulatory bodies, as well as similar governmental authorities in those non-U.S. countries in which we commercialize our products
DroppedRisks Related to Our Intellectual Property
of the Sunshine provisions or any other U.S. federal, state or local laws or regulations that may apply, or if we otherwise fail to comply with the Sunshine provisions or similar requirements of state or local regulators, we may be subject to significant civil, and administrative penalties, damages or fines

Reworded

88% rewrittenRisks Related to Our Intellectual Property
We have incurred, and may in the future incur, substantial costs as a result of litigation or other proceedings relating to patents, other intellectual property rights and related matters, and we may be unable to protect our rights to, or commercialize, our products
Added specific disclosure regarding Chimerix-initiated patent infringement proceedings in Germany against a supplier.
80% rewrittenRisks Related to Controlled Substances
Drug products approved for medical use by FDA that contain cannabis or cannabis extracts may be controlled substances and, if so, will be rescheduled to Schedules II-V after approval, or, like Epidiolex, removed completely from the schedules by operation of other laws
Removed specific references to state-level controlled substance licensing and enforcement sanctions following cannabis drug approvals.
Was: Drug products approved for medical use by FDA that contain cannabis or cannabis extracts may be controlled substances and will be rescheduled to Schedules II-V after approval, or, like Epidiolex, removed completely from the schedules by operation of other laws
73% rewrittenRisks Related to Our Financial Condition and Results
Changes in our effective tax rates could adversely affect our business and financial condition, results of operations and growth prospects
Removed historical reference to a $259.9 million tax expense from 2021 related to U.K. net deferred tax liability remeasurement.
72% rewrittenRisks Related to Our Lead Products and Product Candidates
Delays or problems in the supply of our products for sale or for use in clinical trials, loss of our single source suppliers or failure to comply with manufacturing regulations could materially and adversely affect our business, financial condition, results of operations and growth prospects
Clarified that manufacturing compliance includes strictly enforced U.S. federal regulations alongside state and non-U.S. rules.
70% rewrittenRisks Related to Our Financial Condition and Results
Changes to tax laws relating to multinational corporations could adversely affect us
Updated global minimum tax disclosures to explicitly mention the 15% global minimum tax under OECD Pillar Two.
70% rewrittenRisks Related to Our Intellectual Property
FDA and Equivalent Non-U.S. Regulatory Authorities
Minor phrasing adjustment regarding regulatory authorities' power to withdraw or suspend marketing authorizations.
67% rewrittenRisks Related to Growth of Our Product Portfolio and Research and Development
We may not be able to successfully identify and acquire or in-license additional products or product candidates to grow our business, and, even if we are able to do so, we may otherwise fail to realize the anticipated benefits of these transactions
Changed research and development to the abbreviation R&D in the discussion of business growth strategies.
66% rewrittenRisks Related to Our Lead Products and Product Candidates
Our inability to maintain or increase sales of Epidiolex/Epidyolex would have a material adverse effect on our business, financial condition, results of operations and growth prospects
Added warning that negative developments for Epidiolex in clinical development or foreign jurisdictions may impact commercial results.
64% rewrittenRisks Related to Our Lead Products and Product Candidates
The distribution and sale of our oxybate products are subject to significant regulatory restrictions, including the requirements of a REMS and safety reporting requirements, and these regulatory and safety requirements subject us to risks and uncertainties, any of which could negatively impact sales of Xywav and Xyrem
63% rewrittenRisks Related to Our Intellectual Property
Since Xyrem’s regulatory exclusivity has expired in the EU, we are aware that generic or hybrid generic applications have been approved by various EU regulatory authorities, and additional generic or hybrid generic applications may be submitted and approved
58% rewrittenRisks Related to Our Lead Products and Product Candidates
Recent executive and judicial changes and flux in the regulatory landscape creates uncertainty for us and our industry
57% rewrittenRisks Related to Our Intellectual Property
Significant disruptions of information technology systems or data security incidents could adversely affect our business
Was: Significant disruptions of information technology systems or data security breaches could adversely affect our business
48% rewrittenRisks Related to Our Intellectual Property
With respect to our products and product candidates targeting rare indications, relevant regulatory exclusivities such as orphan drug exclusivity or pediatric exclusivity may not be granted or, if granted, may be limited
46% rewrittenRisks Related to Our Intellectual Property
We and our Third-Party Manufacturers or Suppliers use hazardous materials in our manufacturing facilities, and any claims relating to the improper handling, storage, release or disposal of these materials could be time-consuming and expensive
Was: We use hazardous materials in our manufacturing facilities, and any claims relating to the improper handling, storage, release or disposal of these materials could be time-consuming and expensive
35% rewrittenRisks Related to Our Lead Products and Product Candidates
Our inability to maintain revenues from our oxybate franchise would have a material adverse effect on our business, financial condition, results of operations and growth prospects
33% rewrittenRisks Related to Our Ordinary Shares
If we fail to attract, retain and motivate members of our executive management team and key personnel, our operations and our future growth may be adversely affected
32% rewrittenRisks Related to Our Ordinary Shares
Our workforce initiatives could expose us to the risk of litigation or investigations, resulting in injunctions, penalties, or reputational harm
Was: Anti-diversity, equity and inclusion initiatives could expose us to the risk of litigation or investigations, resulting in injunctions, penalties, or reputational harm
32% rewrittenRisks Related to Our Financial Condition and Results
We have significant intangible assets and goodwill. Consequently, the future impairment of our intangible assets and goodwill may significantly impact our profitability
31% rewrittenRisks Related to Our Intellectual Property
Further, legislation may be introduced at the state or Federal level that, if passed, would, among other things, modify the requirements of the 340B program
30% rewrittenRisks Related to Our Lead Products and Product Candidates
New treatment options for cataplexy and EDS in narcolepsy have been commercially launched and, in the future, other products may be launched that are competitive with, or disrupt the market for, our oxybate products, Xywav and Xyrem
25% rewrittenRisks Related to Our Lead Products and Product Candidates
While we expect Xywav and Epidiolex/Epidyolex to remain our largest products, our success also depends on our ability to effectively commercialize our other existing products and potential future products

All 52 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Lead Products and Product Candidates

01Our inability to maintain revenues from our oxybate franchise would have a material adverse effect on our business, financial condition, results of operations and growth prospects35% rewritten
02New treatment options for cataplexy and EDS in narcolepsy have been commercially launched and, in the future, other products may be launched that are competitive with, or disrupt the market for, our oxybate products, Xywav and Xyrem30% rewritten
03The distribution and sale of our oxybate products are subject to significant regulatory restrictions, including the requirements of a REMS and safety reporting requirements, and these regulatory and safety requirements subject us to risks and uncertainties, any of which could negatively impact sales of Xywav and Xyrem64% rewritten
04Our inability to maintain or increase sales of Epidiolex/Epidyolex would have a material adverse effect on our business, financial condition, results of operations and growth prospects66% rewritten
05While we expect Xywav and Epidiolex/Epidyolex to remain our largest products, our success also depends on our ability to effectively commercialize our other existing products and potential future products25% rewritten
06We face substantial competition from other companies, including companies with larger sales organizations and more experience working with large and diverse product portfolios, and competition from generic drugs
07Recent executive and judicial changes and flux in the regulatory landscape creates uncertainty for us and our industry58% rewritten
08Legislative and regulatory proposals to reform the regulation of the pharmaceutical industry and reimbursement for pharmaceutical drugs are continually changing, and all such considerations may adversely affect our business and industry in ways that we cannot accurately predictNew
09In addition to access, coverage and reimbursement, the commercial success of our products depends upon their market acceptance by physicians, patients, third party payors and the medical community
10Delays or problems in the supply of our products for sale or for use in clinical trials, loss of our single source suppliers or failure to comply with manufacturing regulations could materially and adversely affect our business, financial condition, results of operations and growth prospects72% rewritten
11could negatively impact our anticipated revenues and could potentially cause us to breach contractual obligations with customers or to violate local laws requiring us to deliver the product to those in needNew

Risks Related to Growth of Our Product Portfolio and Research and Development

12We may not realize the anticipated benefits from our acquisition of ChimerixNew
13Our future success depends on our ability to successfully obtain and maintain regulatory approvals for our late-stage product candidates and, if approved, to successfully launch and commercialize those product candidates
14We may not be able to successfully identify and acquire or in-license additional products or product candidates to grow our business, and, even if we are able to do so, we may otherwise fail to realize the anticipated benefits of these transactions67% rewritten
15As a result of these or other factors, products or product candidates we acquire, or obtain licenses to, may not produce the revenues, earnings or business synergies that we anticipated, may not result in regulatory approvals, and may not perform as expectedNew

Risks Related to Our Intellectual Property

16It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection
17Since Xyrem’s regulatory exclusivity has expired in the EU, we are aware that generic or hybrid generic applications have been approved by various EU regulatory authorities, and additional generic or hybrid generic applications may be submitted and approved63% rewritten
18We have incurred, and may in the future incur, substantial costs as a result of litigation or other proceedings relating to patents, other intellectual property rights and related matters, and we may be unable to protect our rights to, or commercialize, our products88% rewritten
19methods do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid or unenforceable, which we may not be able to doNew
20With respect to our products and product candidates targeting rare indications, relevant regulatory exclusivities such as orphan drug exclusivity or pediatric exclusivity may not be granted or, if granted, may be limited48% rewritten
21We have substantially expanded our international footprint and operations, and we may expand further in the future, which subjects us to a variety of risks and complexities which, if not effectively managed, could negatively affect our business
22Significant disruptions of information technology systems or data security incidents could adversely affect our business57% rewritten
23attacks have increased in frequency and severity, and we cannot guarantee that third parties’ infrastructure in our supply chain or our third-party partners’ supply chains have not been compromisedNew
24Our adoption of AI technologies introduces new risks and uncertaintiesNew
25FDA and Equivalent Non-U.S. Regulatory Authorities70% rewritten
26in our revenues from the affected products and harm to our reputation and could have a significant impact on our sales, business and financial conditionNew
27Other Regulatory AuthoritiesNew
28significantly impact the ability of FDA to timely review and process our regulatory submissions or take other actions critical to the marketing of our products which could have a material adverse effect on our businessNew
29Further, legislation may be introduced at the state or Federal level that, if passed, would, among other things, modify the requirements of the 340B program31% rewritten
30Product liability and product recalls could harm our business
31We and our Third-Party Manufacturers or Suppliers use hazardous materials in our manufacturing facilities, and any claims relating to the improper handling, storage, release or disposal of these materials could be time-consuming and expensive46% rewritten

Risks Related to Controlled Substances

32Drug products approved for medical use by FDA that contain cannabis or cannabis extracts may be controlled substances and, if so, will be rescheduled to Schedules II-V after approval, or, like Epidiolex, removed completely from the schedules by operation of other laws80% rewritten
33requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under federal lawNew
34Our ability to research, develop and commercialize Epidiolex/Epidyolex is dependent on our ability to maintain licenses relating to the cultivation, possession and supply of botanical cannabis, a controlled substance
35Controlled substance legislation differs between countries and legislation in certain countries may restrict or limit our ability to sell Epidyolex

Risks Related to Our Financial Condition and Results

36We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial position, and our business would be adversely affected if we are unable to service our debt obligations
37Covenants in the Amended Credit Agreement and indenture governing our Secured Notes restrict our business and operations in many ways and if we do not effectively manage our covenants, our financial conditions and results of operations could be adversely affected
38To continue to grow our business, we will need to commit substantial resources, which could result in future losses or otherwise limit our opportunities or affect our ability to operate and grow our business
39We have significant intangible assets and goodwill. Consequently, the future impairment of our intangible assets and goodwill may significantly impact our profitability32% rewritten
40Our financial results have been and may continue to be adversely affected by foreign currency exchange rate fluctuations
41Changes in our effective tax rates could adversely affect our business and financial condition, results of operations and growth prospects73% rewritten
42We are subject to reviews and audits by the IRS, and other taxing authorities from time to time, and the IRS or other taxing authority may challenge our structure, transfer pricing arrangements and tax positions through an audit or lawsuitNew
43Changes to tax laws relating to multinational corporations could adversely affect us70% rewritten
44The IRS may not agree with the conclusion that we should be treated as a foreign corporation for U.S. federal tax purposes
45Our ability to use NOLs and carryforward tax losses to offset potential taxable income is limited under applicable law and could be subject to further limitations if we do not generate taxable income in a timely manner or if certain “ownership change” provisions of applicable law result in further limitations

Risks Related to Our Ordinary Shares

46The market price of our ordinary shares has been volatile and is likely to continue to be volatile in the future, and the value of your investment could decline significantly
47We are subject to Irish law, which differs from the laws in effect in the U.S. and may afford less protection to holders of our securities
48Our articles of association, Irish law, the Amended Credit Agreement and the indentures governing our Secured Notes and Exchangeable Senior Notes contain provisions that could delay or prevent a takeover of us by a third party
49We have never declared or paid dividends on our capital stock and we do not anticipate paying dividends in the foreseeable future
50If we fail to attract, retain and motivate members of our executive management team and key personnel, our operations and our future growth may be adversely affected33% rewritten
51Our workforce initiatives could expose us to the risk of litigation or investigations, resulting in injunctions, penalties, or reputational harm32% rewritten
52Our business and operations could be negatively affected if we become subject to shareholder activism or hostile bids, which could cause us to incur significant expense, hinder execution of our business strategy and impact our stock price

Other Jazz Pharmaceuticals 10-Ks

FY2024 10-K risk factors
46 risks
Revenue concentration on the oxybate franchise and Epidiolex dominates risk exposure.
Filed Feb 26, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.